AI in Drug Discovery: A Review of US & EU Policy Guidance

Navigating Policy to Unlock AI’s Full Potential in Drug Discovery

Artificial intelligence is transforming drug discovery — accelerating timelines, improving accuracy, and enabling novel therapeutic development. This whitepaper reviews the latest US and EU policy guidance, including the FDA’s evolving AI/ML framework, the EU AI Act, and EMA’s recommendations, providing life sciences organizations with a roadmap for responsible and effective AI adoption.

Inside

Understand how AI is reshaping the drug discovery process from molecule design to repurposing.

Learn about US regulatory initiatives, including the FDA’s AI/ML Action Plan and forthcoming guidance.

Explore the EU AI Act and EMA’s human-centric approach to AI in medicine development.

See how global AI safety initiatives are influencing healthcare innovation.

Discover how to align AI-driven R&D with ethical, legal, and compliance standards.